Linagliptin/Metformin 1 A Pharma

Linagliptin/Metformin, the active ingredient in Linagliptin/Metformin 1 A Pharma, is a DPP‑4 inhibitor and biguanide presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve blood glucose control when used alone or in combination with other antidiabetic agents.

GNH USA supplies Linagliptin/Metformin 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is distributed under strict regulatory compliance.

Linagliptin/Metformin is used in the treatment of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus (initial therapy): provides glycemic control as first‑line oral treatment. - Type 2 diabetes mellitus (add‑on therapy): enhances glucose lowering when combined with other agents such as sulfonylureas or insulin. - Type 2 diabetes mellitus (fixed‑dose combination): offers a single tablet option that simplifies regimen and may improve adherence.

Linagliptin/Metformin may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Headache - Upper respiratory tract infection - Dizziness

Serious or Rare Side Effects: - Lactic acidosis (especially in renal impairment) - Severe hypoglycemia when combined with insulin or sulfonylureas - Acute pancreatitis - Hepatic dysfunction - Anaphylactic reactions - Renal failure

When prescribing Linagliptin/Metformin, clinicians should consider several precautionary measures to ensure patient safety.

- Renal function: assess baseline eGFR and monitor periodically, as metformin is renally cleared. - Hepatic function: use with caution in patients with liver disease. - Lactic acidosis risk: avoid in patients with severe renal impairment or conditions predisposing to hypoxia. - Pregnancy and lactation: safety not established; discuss risks with healthcare provider. - Drug interactions: review concomitant medications for potential interactions that may affect glucose control or metformin accumulation. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Linagliptin/Metformin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin exposure. - Iodinated contrast agents in patients with renal impairment: heightened risk of metformin‑associated lactic acidosis. - Sulfonylureas or insulin: increased risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - Beta‑blockers: may mask symptoms of hypoglycemia.